Submitted by Nicola-Swanborough on Wed, 29/06/2016 - 13:32
Latest trial into the use of a cannabis-based drug for the treatment of a highly drug-resistant form of epilepsy shows positive results.
Submitted by olivia-rzadkiewicz on Tue, 12/04/2016 - 16:17
GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).
Submitted by Nicola-Swanborough on Mon, 14/03/2016 - 14:35
Epilepsy Society's medical director Professor Ley Sander welcomes the latest results from the first placebo-controlled trial into the cannabis-based drug Epidiolex.
Submitted by Nicola-Swanborough on Wed, 06/01/2016 - 11:01
US-based study show that a cannabis-based treatment may have the potential to reduce seizure frequency in children and young adults with highly resistant epilepsy.